Parents of children with autism are increasingly pursuing a treatment called leucovorin, a derivative of vitamin B9, despite hesitations from the medical community regarding its efficacy for autism. This surge in interest followed a press conference where federal health officials suggested that leucovorin could benefit many children with autism, leading to a wave of hope among parents like Swathi Balantrapu, whose ten-year-old son has the condition.
Balantrapu has explored numerous treatments for her son, including applied behavior analysis (ABA) therapy and a movement program costing around $7,000. She even considered a stem cell therapy in Germany priced at $40,000 annually. The recent announcement about leucovorin ignited a new sense of possibility for her. “I would do anything for my child,” she stated, expressing the desire for a treatment that could potentially help her son.
In the wake of the federal announcement, which claimed that leucovorin could assist children suffering from cerebral folate deficiency—a rare condition—they also implied it could aid “hundreds of thousands” of autistic children. This statement led to a significant increase in demand for the drug, with parents forming online groups to share information about doctors who might prescribe it.
Medical Community Divided Over Leucovorin
Major medical organizations have voiced concerns about prescribing leucovorin for autism. While the use of this drug for cerebral folate deficiency is well-established and non-controversial, experts criticized the government’s communication, suggesting it misrepresented the drug’s applicability to a broader autism population. Dr. Shafali Jeste, an autism researcher at the University of California, Los Angeles, remarked, “There’s this onslaught of information being disseminated that we now have to explain, disentangle and interpret.”
The FDA has since clarified that the approval of leucovorin is limited to a specific subset of patients with FOLR1-related cerebral folate transport deficiency, a condition with fewer than 50 documented cases globally. A senior FDA official stated, “Right now we don’t have sufficient data to say that we could establish efficacy for autism more broadly,” emphasizing the need for patients to consult with their doctors regarding the treatment.
Despite this clarification, the initial announcement has had lasting effects on public perception. Many parents left the press conference believing that leucovorin was a proven treatment for autism, a notion that Dr. Frederick Bassal of the University of California, Davis, noted was not supported by sufficient scientific evidence.
Social Media Drives Demand
The online response has been overwhelming, with communities forming on platforms like Facebook and Telegram, where parents share experiences and seek out prescribers. One group alone attracted around 80,000 members, illustrating the collective drive for access to leucovorin. Keith Joyce, a moderator of one such group, noted the frustration among parents when mainstream medical providers declined to prescribe the drug, stating, “Many doctors were saying, ‘I’m not going to prescribe it simply because there’s not enough information.’”
The demand for leucovorin prescriptions surged, with a reported increase of 71% in the last quarter of 2025. This trend underscores the influence that public figures and government announcements can have on healthcare practices. Joyce described the recent FDA announcement limiting the drug’s approval as “maddening,” suggesting that it complicates the path for families seeking prescriptions.
Despite the lack of consensus within the medical community, some healthcare providers are willing to prescribe leucovorin. Dr. Richard Frye, who operates a private practice, reports that approximately 80% of his autism patients receive prescriptions for the drug. He is an advocate for leucovorin, linking its potential benefits to unproven theories about autism and mitochondrial dysfunction. Conversely, many larger health systems, including Kaiser Permanente, have opted to withhold prescriptions pending further research into the drug’s safety and effectiveness.
The situation has left parents in a difficult position. They must not only find a willing physician but also navigate the costs associated with obtaining the medication. Some private practices charge significantly for consultations, with fees ranging from $150 to $1,500 for initial visits. Balantrapu, upon discovering the high costs associated with securing a prescription, ultimately decided against pursuing it further.
The controversy surrounding leucovorin is emblematic of a broader issue in autism treatment. While some doctors are open to prescribing it, others argue that doing so based on parental demand could set a dangerous precedent. Dr. Sarah Mohiuddin, who directs the Multidisciplinary Autism Program at Michigan Medicine, emphasized the need for careful consideration in prescribing practices, stating, “It’s a complicated risk-benefit analysis.”
As the debate continues, the gap between parents seeking new treatments and medical professionals advocating for evidence-based practices remains wide. The balance between fostering trust with families and adhering to scientific rigor presents ongoing challenges for clinicians.
In a landscape marked by uncertainty, the quest for effective autism treatments continues, underscoring the urgency that many parents feel to explore every possible avenue for their children’s well-being.
